Efficacy of Control-IQ Technology in a General Endocrine Clinic
Authors' conclusion
The Control-IQ technology system was effective in reducing hyperglycemia while increasing time in target range and decreasing hypoglycemia. This technology is a useful and effective addition to the growing number of automated insulin delivery systems. The clinical outcomes mirror the results found in the key adult pivotal trials.
Study context
- Population
- Adults with T1D or T2D transitioned to Tandem t:slim X2 with Control-IQ, general endocrine clinic, January 2020 to June 2021Adults with T1D 61 · or T2D 5
- Participants
- 66 adults
- Exposure
- Post- vs pre-Control-IQ technology
- Outcome
- Change in TIR with Control-IQ technology
Methodological detailsbefore-after comparison, single-clinic
- Before-after comparison
- Single-clinic
Main finding
As reported in the abstract
TIR
P < 0.0003
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Time above rangeReduction after transitioning to Control-IQ | P < 0.0013 |
| Time below rangeDecrease after transitioning to Control-IQ | P = 0.017 |
| HbA1cDecrease after transitioning to Control-IQ | P < 0.017 |
Time above range
- Reduction in time above range after transitioning to Control-IQ
Time below range
- Decrease in time below range after transitioning to Control-IQ
HbA1c
- Decrease in HbA1c after transitioning to Control-IQ
Patient dropout rate
- Patient dropout rate was low
- 7%
Original publication
Efficacy of Control-IQ Technology in a General Endocrine Clinic. Endocr Pract. Published 22 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →